[Form 4] Alzamend Neuro, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 07/30/2024, Grindr Inc. (GRND) filed a Form 4 detailing an insider equity award to director and 10% owner George Raymond Zage III. He received 6,669 restricted stock units (RSUs) at no cost. The RSUs vest 25% on 10/30/2025 and the remainder in equal quarterly installments, conditioned on continued service under the 2022 Equity Incentive Plan.

Following the grant, Zage’s direct ownership rises to 6,733,283 common shares. He also maintains indirect control of 85,926,333 shares through Tiga Eighty-Eight Pte Ltd and 1,060,507 shares via Big Timber Holdings LLC. No shares were sold and no derivative positions were reported.

The incremental grant is immaterial relative to Zage’s existing >10% stake and does not alter float or signal operational developments. The filing is principally a routine disclosure of executive compensation and ownership structure.

Insights

SEC Compliance Analyst

TL;DR: Routine RSU award to large shareholder; no market-moving details.

This Form 4 records a small equity incentive—6,669 RSUs—granted to George Zage. It modestly increases his direct holding but leaves his aggregate beneficial ownership effectively unchanged at roughly 93.7 million shares. The zero-cost grant aligns compensation with shareholder value but is far too small to influence governance or control dynamics. Because no dispositions occurred and vesting is long-dated, I view the filing as procedural, not price-sensitive.

Portfolio Manager

TL;DR: De minimis addition; neutral for GRND valuation.

The grant equals <0.01% of GRND’s float and does not change insider ownership concentration. Absence of sales is mildly reassuring, yet the scale is immaterial for earnings, dilution, or float tightening. I do not expect trading impact or need to adjust position sizing based on this disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AULT MILTON C III

(Last) (First) (Middle)

11411 SOUTHERN HIGHLANDS PARKWAY

SUITE 190

(Street)

LAS VEGAS NV 89141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ ALZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2025		C		100,000(1)	A	$2.32	137,709	I	By Ault Lending, LLC(2)
Common Stock	07/30/2025		S		29,449	D	$2.5122(3)	108,260	I	By Ault Lending, LLC(2)
Common Stock	07/31/2025		S		100,000	D	$2.2155(4)	8,260	I	By Ault Lending, LLC(2)
Common Stock								1,843	D
Common Stock								11,068	I	By Ault Life Sciences, Inc.(5)
Common Stock								61	I	By Ault Life Sciences Fund, LLC(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	$2.32(7)	07/30/2025		C			232	01/31/2024	(8)	Common Stock	100,000	$1,000	1,535.2447	I	By Ault Lending, LLC(2)
Common Stock Purchase Warrants	$108							08/01/2024	08/01/2029	Common Stock	13,556		13,556	I	By Ault Lending, LLC(2)
Common Stock Purchase Warrants	$108							09/27/2024	09/27/2029	Common Stock	8,667		8,667	I	By Ault Lending, LLC(2)
Common Stock Purchase Warrants	$108							10/30/2024	10/30/2029	Common Stock	1,111		1,111	I	By Ault Lending, LLC(2)
Common Stock Purchase Warrants	$4,050							08/31/2020	08/31/2025	Common Stock	12		12	I	By Hyperscale Data, Inc.(9)

Explanation of Responses:

1. Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred").

2. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

3. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.5122. The range of sales prices on the transaction date was $2.4047 to $2.6367 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

4. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.2155. The range of sales prices on the transaction date was $2.1628 to $2.2511 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

5. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

6. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

7. The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock.

8. The shares of Series B Preferred have no expiration date.

9. Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by HSD.

Remarks:

	/s/ Milton C. Ault, III	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.